Literature DB >> 10556035

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

H Wu1, Y Nie, W D Huse, J D Watkins.   

Abstract

Optimal protein function often depends on co-operative interactions between amino acid residues distant in the protein primary sequence yet spatially near one another following protein folding. For example, antibody affinity is influenced by interactions of framework residues with complementarity-determining region (CDR) residues. However, despite the abundance of antibody structural information and computational tools the humanization of rodent antibodies for clinical use often results in a significant loss of affinity. To date, antibody engineering efforts have focused either on optimizing CDR residues involved in antigen binding or on optimizing antibody framework residues that serve critical roles in preserving the conformation of CDRs. In the present study a new approach which permits the rapid identification of co-operatively interacting framework and CDR residues was used to simultaneously humanize and optimize a murine antibody directed against CD40. Specifically, a combinatorial library that examined eight potentially important framework positions concomitantly with focused CDR libraries consisting of variants containing random single amino acid mutations in the third CDR of the heavy and light chains was expressed. Multiple anti-CD40 Fab variants containing as few as one murine framework residue and displaying up to approximately 500-fold higher affinity than the initial chimeric Fab were identified. The higher affinity humanized variants demonstrated a co-operative interaction between light chain framework residue Y49 and heavy chain CDR3 residue R/K101 (coupling energy, DeltaGI=0.9 kcal/mol). Screening of combinatorial framework-CDR libraries permits identification of monoclonal antibodies (mAb) with structures optimized for function, including instances in which the antigen induces conformational changes in the mAb. Moreover, the enhanced humanized variants contain fewer murine framework residues and could not be identified by sequential in vitro humanization and affinity muturation strategies. This approach to identifying co-operatively interacting residues is not restricted to antibody-antigen interactions and consequently, may be used broadly to gain insight into protein structure-function relationships, including proteins that serve as catalysts. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556035     DOI: 10.1006/jmbi.1999.3141

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  6 in total

1.  A general method for greatly improving the affinity of antibodies by using combinatorial libraries.

Authors:  Arvind Rajpal; Nurten Beyaz; Lauric Haber; Guido Cappuccilli; Helena Yee; Ramesh R Bhatt; Toshihiko Takeuchi; Richard A Lerner; Roberto Crea
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-06       Impact factor: 11.205

Review 2.  Guide to Selecting a Biorecognition Element for Biosensors.

Authors:  Marissa A Morales; Jeffrey Mark Halpern
Journal:  Bioconjug Chem       Date:  2018-09-28       Impact factor: 4.774

Review 3.  Linkers Having a Crucial Role in Antibody-Drug Conjugates.

Authors:  Jun Lu; Feng Jiang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-04-14       Impact factor: 5.923

Review 4.  Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.

Authors:  Rotimi Sheyi; Beatriz G de la Torre; Fernando Albericio
Journal:  Pharmaceutics       Date:  2022-02-11       Impact factor: 6.321

5.  Generation of monoclonal antibody MS17-57 targeting secreted alkaline phosphatase ectopically expressed on the surface of gastrointestinal cancer cells.

Authors:  Ming Li; Jianpeng Gao; Runhua Feng; Yuling Wang; Xuehua Chen; Jianyu Sun; Dongqing Zhang; Zhenggang Zhu; Lee M Ellis; Mason Lu; Jeffrey E Lee; Zhenqing Feng; Bingya Liu
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

6.  Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.

Authors:  Ling Liu; Jirong Lu; Barrett W Allan; Ying Tang; Jonathan Tetreault; Chi-Kin Chow; Barbra Barmettler; James Nelson; Holly Bina; Lihua Huang; Victor J Wroblewski; Kristine Kikly
Journal:  J Inflamm Res       Date:  2016-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.